7 Analysts Have This to Say About IDEAYA Biosciences
Portfolio Pulse from Benzinga Insights
In the last quarter, IDEAYA Biosciences (NASDAQ:IDYA) received 7 analyst ratings, with 1 being bullish and 6 somewhat bullish. The company's average 12-month price target is $36.0, an increase of 11.35% from the previous average of $32.33.
September 12, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IDEAYA Biosciences received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. In this case, IDEAYA Biosciences received mostly positive ratings, which could lead to increased investor confidence and a potential rise in the stock price. The increase in the average 12-month price target also indicates a positive outlook for the company.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100